Analyses of the urinary and gut microbiomes and a quality improvement to standardize use of antibiotics after prostate biopsy were among other AUA 2016 highlights in this therapeutic area.
Christina B. Ching, MDAnalyses of the urinary and gut microbiomes and a quality improvement to standardize use of antibiotics after prostate biopsy were among AUA 2016 highlights in this therapeutic area. The infection/inflammation take-home messages were presented by Christina B. Ching, MD, of Nationwide Children's Hospital, Columbus, OH.
An examination of urine showed increased toxic urinary cations in males with interstitial cystitis (IC), providing potential mechanistic insight for the cause of IC/bladder pain syndrome.
Differential expression of a multi-marker panel of chemokines can distinguish between normal and decreased bladder capacity in IC patients. The finding could allow for phenotypic characterization of IC using a biomarker.
In a study involving a new class of agents for the treatment of IC known as SHIP activators, AQX-1125 decreased visceral pain and bladder inflammation in a rat model. Also, a randomized, double-blind, placebo-controlled phase II trial showed SHIP-1 activation provides significantly improved pain scores and scores on standardized questionnaires.
Agents that improve abdominal pain may be able to improve urologic symptoms through common sensory innervation pathways.
The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and controls as well as between patients with different clinical phenotypes, with the urinary microbiome in CP/CPPS patients having significantly increased alpha diversity. An analysis of the gut microbiome also revealed significant difference between men with CP/CPPS and controls, with the gut microbiome in CP/CPPS patients having significantly decreased alpha diversity.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.